HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

NSC305787

an ezrin inhibitor and antineoplastic agent; structure in first source

Networked: 4 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Alicyclic Hydrocarbons: 1
      - Cycloparaffins: 6
        Adamantane: 182
        NSC305787: 4
    - Bridged-Ring Compounds: 1
      - Adamantane: 182
        NSC305787: 4
Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinolines: 146
      - NSC305787: 4

Experts

1.	Lima, Keli: 2 articles (01/2022 - 10/2021)
2.	Lipreri da Silva, Jean Carlos: 2 articles (01/2022 - 10/2021)
3.	Machado-Neto, João Agostinho: 2 articles (01/2022 - 10/2021)
4.	Carvalho, Maria Fernanda Lopes: 1 article (01/2022)
5.	de Almeida, Bruna Oliveira: 1 article (01/2022)
6.	de Miranda, Livia Bassani Lins: 1 article (01/2022)
7.	Coelho-Silva, Juan Luiz: 1 article (10/2021)
8.	Costa-Lotufo, Leticia Veras: 1 article (10/2021)
9.	Lazarini, Mariana: 1 article (10/2021)
10.	Traina, Fabiola: 1 article (10/2021)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2022 - "Our exploratory molecular studies identified that NSC305787 modulates the expression and activation of key regulators of the cell cycle, proliferation, DNA damage, and apoptosis, favoring a tumor-suppressive molecular network. " 01/19/2012 - "The small molecule inhibitors NSC305787 and NSC668394 demonstrate a novel targeted therapy that directly inhibits ezrin protein as an approach to prevent tumor metastasis."
2.	Osteosarcoma (Osteogenic Sarcoma) 06/17/2016 - "In addition, we validated the anti-metastatic effects of NSC305787 in reducing the incidence of lung metastasis in a genetically engineered mouse model of osteosarcoma and evaluated the pharmacokinetics of NSC305787 and NSC668394 in mice. " 06/17/2016 - "In this study, to uncover specific cellular responses evoked by ezrin inhibition that can be used as a specific pharmacodynamic marker(s), we profiled global gene expression in osteosarcoma cells after treatment with small molecule ezrin inhibitors, NSC305787 and NSC668394. "
3.	Pancreatic Neoplasms (Pancreatic Cancer) 01/01/2022 - "Our study identifies a novel molecular axis underlying the antineoplastic activity of NSC305787 and provides insights into the development of therapeutic strategies for pancreatic cancer." 01/01/2022 - "We also assessed the potential antineoplastic effects of NSC305787 in pancreatic cancer cell lines. " 01/01/2022 - "NSC305787, a pharmacological ezrin inhibitor, exhibits antineoplastic activity in pancreatic cancer cells."
4.	Neoplasm Metastasis (Metastasis) 06/17/2016 - "In addition, we validated the anti-metastatic effects of NSC305787 in reducing the incidence of lung metastasis in a genetically engineered mouse model of osteosarcoma and evaluated the pharmacokinetics of NSC305787 and NSC668394 in mice. " 01/19/2012 - "The small molecule inhibitors NSC305787 and NSC668394 demonstrate a novel targeted therapy that directly inhibits ezrin protein as an approach to prevent tumor metastasis."
5.	Leukemia 10/01/2021 - "NSC305787 had a greater potency and efficiency than NSC668394 in leukemia models. "

Related Drugs and Biologics

1.	NSC668394
2.	ezrin
3.	Antineoplastic Agents (Antineoplastics)
4.	Proteins (Proteins, Gene)

Related Therapies and Procedures

1.	Aftercare (After-Treatment)
2.	Therapeutics